Amonrat Jumnainsong
Khon Kaen University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Amonrat Jumnainsong.
Science | 2010
Wanwisa Dejnirattisai; Amonrat Jumnainsong; Naruthai Onsirisakul; Patricia Fitton; Sirijitt Vasanawathana; Wannee Limpitikul; Chunya Puttikhunt; Carolyn Edwards; Thaneeya Duangchinda; Sunpetchuda Supasa; Kriangkrai Chawansuntati; Prida Malasit; Juthathip Mongkolsapaya; Gavin R. Screaton
Dangerous Dengue Provocation One problem with dengue virus is that one infection does not protect against a subsequent infection; secondary infections can result in the severe immunopathology of dengue hemorrhagic fever. Dejnirattisai et al. (p. 745) derived a panel of monoclonal antibodies specific for dengue viruses. These antibodies were mainly directed against the dengue virus precursor membrane protein (prM), and most cross-reacted with all four dengue serotypes. The antibodies were not capable of fully neutralizing the virus, but instead promoted immune responses over a wide range of concentrations. During virus production and virion assembly, maturation of prm is often incomplete, and, consequently, a major part of the hosts natural antibody response recognizes a component that is present in variable numbers on the virion. Thus, rather than resulting in complete neutralization, the antibody response promotes virus infection of cells that carry receptors for antibodies. Variable maturation of a dengue viral antigen results in incomplete neutralization and promotes secondary pathology. Dengue virus co-circulates as four serotypes, and sequential infections with more than one serotype are common. One hypothesis for the increased severity seen in secondary infections is antibody-dependent enhancement (ADE) leading to increased replication in Fc receptor–bearing cells. In this study, we have generated a panel of human monoclonal antibodies to dengue virus. Antibodies to the structural precursor-membrane protein (prM) form a major component of the response. These antibodies are highly cross-reactive among the dengue virus serotypes and, even at high concentrations, do not neutralize infection but potently promote ADE. We propose that the partial cleavage of prM from the viral surface reduces the density of antigen available for viral neutralization, leaving dengue viruses susceptible to ADE by antibody to prM, a finding that has implications for future vaccine design.
Nature Immunology | 2015
Wanwisa Dejnirattisai; Wiyada Wongwiwat; Sunpetchuda Supasa; Xiaokang Zhang; Xinghong Dai; Alexander Rouvinski; Amonrat Jumnainsong; Carolyn Edwards; Nguyen Than Ha Quyen; Thaneeya Duangchinda; Jonathan M. Grimes; Wen-Yang Tsai; Chih-Yun Lai; Wei-Kung Wang; Prida Malasit; Jeremy Farrar; Cameron P. Simmons; Z. Hong Zhou; Félix A. Rey; Juthathip Mongkolsapaya; Gavin R. Screaton
Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
Journal of Immunology | 2012
Claire M. Midgley; Aleksandra Flanagan; Hai Bac Tran; Wanwisa Dejnirattisai; Kriangkrai Chawansuntati; Amonrat Jumnainsong; Wiyada Wongwiwat; Thaneeya Duangchinda; Juthathip Mongkolsapaya; Jonathan M. Grimes; Gavin R. Screaton
Dengue virus infections are still increasing at an alarming rate in tropical and subtropical countries, underlying the need for a dengue vaccine. Although it is relatively easy to generate Ab responses to dengue virus, low avidity or low concentrations of Ab may enhance infection of FcR-bearing cells with clinical impact, posing a challenge to vaccine production. In this article, we report the characterization of a mAb, 2H12, which is cross-reactive to all four serotypes in the dengue virus group. Crystal structures of 2H12-Fab in complex with domain III of the envelope protein from three dengue serotypes have been determined. 2H12 binds to the highly conserved AB loop of domain III of the envelope protein that is poorly accessible in the mature virion. 2H12 neutralization varied between dengue serotypes and strains; in particular, dengue serotype 2 was not neutralized. Because the 2H12-binding epitope was conserved, this variation in neutralization highlights differences between dengue serotypes and suggests that significant conformational changes in the virus must take place for Ab binding. Surprisingly, 2H12 facilitated little or no enhancement of infection. These data provide a structural basis for understanding Ab neutralization and enhancement of infection, which is crucial for the development of future dengue vaccines.
The Journal of Infectious Diseases | 2011
Wanwisa Dejnirattisai; Andrew I. Webb; Vera Sau-Fong Chan; Amonrat Jumnainsong; Andrew D. Davidson; Juthathip Mongkolsapaya; Gavin R. Screaton
Dengue virus receptors are relatively poorly characterized, but there has been recent interest in 2 C-type lectin molecules, dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN) and its close homologue liver/lymph node-specific ICAM-3-grabbing integrin (L-SIGN), which can both bind dengue and promote infection. In this report we have studied the interaction of dengue viruses produced in insect cells, tumor cell lines, and primary human dendritic cells (DCs) with DC-SIGN and L-SIGN. Virus produced in primary DCs is unable to interact with DC-SIGN but remains infectious for L-SIGN-expressing cells. Skin-resident DCs may thus be a site of initial infection by insect-produced virus, but DCs will likely not participate in large-scale virus replication during dengue infection. These results reveal that differential glycosylation of dengue virus envelope protein is highly dependent on cell state and suggest that studies of virus tropism using virus prepared in insect cells or tumor cell lines should be interpreted with caution.
Journal of Virology | 2013
Wen-Yang Tsai; Chih-Yun Lai; Yi-Chieh Wu; Hong-En Lin; Carolyn Edwards; Amonrat Jumnainsong; Srisakul Kliks; Scott B. Halstead; Juthathip Mongkolsapaya; Gavin R. Screaton; Wei-Kung Wang
ABSTRACT The envelope (E) protein of dengue virus (DENV) is the major target of neutralizing antibodies (Abs) and vaccine development. Previous studies of human dengue-immune sera reported that a significant proportion of anti-E Abs, known as group-reactive (GR) Abs, were cross-reactive to all four DENV serotypes and to one or more other flaviviruses. Based on studies of mouse anti-E monoclonal antibodies (MAbs), GR MAbs were nonneutralizing or weakly neutralizing compared with type-specific MAbs; a GR response was thus not regarded as important for vaccine strategy. We investigated the epitopes, binding avidities, and neutralization potencies of 32 human GR anti-E MAbs. In addition to fusion loop (FL) residues in E protein domain II, human GR MAbs recognized an epitope involving both FL and bc loop residues in domain II. The neutralization potencies and binding avidities of GR MAbs derived from secondary DENV infection were stronger than those derived from primary infection. GR MAbs derived from primary DENV infection primarily blocked attachment, whereas those derived from secondary infection blocked DENV postattachment. Analysis of the repertoire of anti-E MAbs derived from patients with primary DENV infection revealed that the majority were GR, low-avidity, and weakly neutralizing MAbs, whereas those from secondary infection were primarily GR, high-avidity, and potently neutralizing MAbs. Our findings suggest that the weakly neutralizing GR anti-E Abs generated from primary DENV infection become potently neutralizing MAbs against the four serotypes after secondary infection. The observation that the dengue immune status of the host affects the quality of the cross-reactive Abs generated has implications for new strategies for DENV vaccination.
Journal of Microbiology | 2013
Kanya Klumkrathok; Amonrat Jumnainsong; Chanvit Leelayuwat
Unique long 16 (UL16) is a viral glycoprotein produced in a host cell infected with human cytomegalovirus (HCMV). It down regulates surface expression of MICB, one of the NKG2D ligands, by forming stable intracellular complexes and retained in the endoplasmic reticulum. Down expression of MICB renders cells less susceptible to NK cell lysis via the NKG2D receptor. Diverse UL16 sequences were identified from different strains of HCMV. MICB is known to be polymorphic. It is not known whether these polymorphisms affect the interactions between these molecules leading to alteration of the immune surveillance of HCMV. The soluble Fc fusion variant UL16 proteins from four laboratory and clinical isolates (AD169, Toledo, PH, and TR) were produced. Four allelic MICB alleles (008, 003, 004, and 00502) were cloned and stable cell lines expressing these MICB alleles were produced. The binding activities of variant UL16 to allelic MICB proteins were determined by flow cytometry. The variants of UL16 proteins did not affect the binding activities to allelic MICB proteins. However, diverse MICB alleles differentially bound UL16. We found that MICB*008 which contains methionine and asparagine at the amino acid positions 98 and 113, respectively, in the alpha 2 domain showed decreased binding activities to UL16 when compared to MICB*003, 004, and MICB*00502 containing isoleucine and aspartic acid, respectively. This finding may imply that MICB*008 is a protective allele and involved in the immune surveillance of HCMV infected patients.
Genes | 2017
Wipaporn Wongfieng; Amonrat Jumnainsong; Yaovalux Chamgramol; Banchob Sripa; Chanvit Leelayuwat
The treatment of cancer through the induction of natural killer group 2, member D (NKG2D) ligands is of interest, but understanding of mechanisms controlling expression of individual ligand is limited. The major histocompatibility complex (MHC) class I chain related protein B (MICB) is a member of NKG2D ligands. We aimed to investigate the role of 3′-untranslated (3′-UTR) and 5′-untranslated regions (5′-UTR) in post-transcriptional regulation of MICB. Nine novel microRNAs (miRNAs) predicted to interact with 3′-UTR and 5′-UTR using TargetScan, RNAhybrid and miBridge were identified. Their regulation of 3′-UTR, 5′-UTR and both 3′- and 5′-UTR sequences of MICB were indicated by the reduction of luciferase activities of luciferase reporter constructs. Mutations of miRNA binding sites at 3′- and 5′-UTRs resulted in increased luciferase activities confirming the regulation of nine candidate miRNAs. In addition, overexpression of candidate miRNAs also down-regulated the expression of reporter constructs. Consequently, the overexpression and inhibition of candidate miRNAs lead to the decreased and increased. MICB protein expressions on the cells tested, respectively. This study has identified a new role of miRNAs in regulation of MICB expression via both 3′-UTR and 5′-UTR sequences applicable for cancer immunotherapy.
OncoTargets and Therapy | 2014
Achara Phumyen; Siriporn Jantasorn; Amonrat Jumnainsong; Chanvit Leelayuwat
Background Cancer therapy by systemic administration of anticancer drugs, besides the effectiveness shown on cancer cells, demonstrated the side effects and cytotoxicity on normal cells. The targeted drug-carrying nanoparticles may decrease the required drug concentration at the site and the distribution of drugs to normal tissues. Overexpression of major histocompatibility complex class I chain–related A (MICA) in cancer is useful as a targeted molecule for the delivery of doxorubicin to MICA-expressing cell lines. Methods The application of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) chemistry was employed to conjugate the major coat protein of bacteriophages carrying anti-MICA and doxorubicin in a mildly acid condition. Doxorubicin (Dox) on phages was determined by double fluorescence of phage particles stained by M13-fluorescein isothiocyanate (FITC) and drug autofluorescence by flow cytometry. The ability of anti-MICA on phages to bind MICA after doxorubicin conjugation was evaluated by indirect enzyme-linked immunosorbent assay. One cervical cancer and four cholangiocarcinoma cell lines expressing MICA were used as models to evaluate targeting activity by cell cytotoxicity test. Results Flow cytometry and indirect enzyme-linked immunosorbent assay demonstrated that most of the phages (82%) could be conjugated with doxorubicin, and the Dox-carrying phage-displaying anti-MICA (Dox-phage) remained the binding activity against MICA. Dox-phage was more efficient than free drugs in killing all the cell lines tested. The half maximal inhibitory concentration (IC50) values of Dox-phage were lower than those of free drugs at approximately 1.6–6 times depending on MICA expressions and the cell lines tested. Conclusion Evidently, the application of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide chemistry is effective to conjugate doxorubicin and major coat protein of bacteriophages without destroying binding activity of MICA antibodies. Dox-carrying bacteriophages targeting MICA have been successfully developed and may enable a broad range of applications in cancer-targeting chemotherapy.
Journal of Traditional Chinese Medicine | 2017
Lin Shihang; Wichai Eungpinithpong; Amonrat Jumnainsong; Somchai Rattanathongkom
Abstract Objective To investigate the effects of acupuncture therapy compared with sham acupuncture on heart rate variability (HRV) in 24 elite soccer players during 4-week, high-intensity training sessions. Methods The subjects were randomly divided into two groups: acupuncture group (AG) and sham acupuncture group (SG). In addition, AG had been implemented two times/week to stimulate Zusanli (ST 36), Hegu (LI 4), Shenshu (BL 23), and Chize (LU 5). While SG, had been applied to utilize a special “placebo-needle” technique on the same sites. Whats more, the HRV parameters were calculated before and after interventions, respectively. Results First, stress index (SI) had a significantly increased in SG (P = 0.031) compare pre-test with post-test, however, no significantly difference in AG (P = 0.102). Secondly, standard deviation of N-N intervals (SNDD) have enormously significantly higher in AG when comparing baseline with post therapy (P = 0.001), while, declined in SG (P = 0.827). Meanwhile, the root mean square of successive differences (RMSSD) were significant differences in AG (P = 0.023). Whats more, when the high-frequency (HF) were significantly higher in AG (P = 0.047) after receiving the acupuncture therapy, the lowe-frequency (LF) power were decreased but no significant in AG and SG. Comparing with pre-experiment, the ratio of LF/HF was lower in AG, but higher in SG. Furthermore, it was significant difference when compare the post-experiment parameters of AG with SG (P = 0.015). And HF parameters have significance (P = 0.005) compare between two groups during the post-experiment. Conclusion Based on evidence, acupuncture therapy on special acupoints could strengthen the parasympathetic nervous activity and modulates the balance between parasympathetic and sympathetic activity in soccer players while they engage in high-intensity training.
Nature Immunology | 2015
Wanwisa Dejnirattisai; Wiyada Wongwiwat; Sunpetchuda Supasa; Xiaokang Zhang; Xinghong Dai; Alexander Rouvinsky; Amonrat Jumnainsong; Carolyn Edwards; Nguyen Than Ha Quyen; Thaneeya Duangchinda; Jonathan M. Grimes; Wen Yang Tsai; Chih Yun Lai; Wei-Kung Wang; Prida Malasit; Jeremy Farrar; Cameron P. Simmons; Z. Hong Zhou; Félix A. Rey; Juthathip Mongkolsapaya; Gavin R. Screaton
Wanwisa Dejnirattisai, Wiyada Wongwiwat, Sunpetchuda Supasa, Xiaokang Zhang, Xinghong Dai, Alexander Rouvinsky, Amonrat Jumnainsong, Carolyn Edwards, Nguyen Than Ha Quyen, Thaneeya Duangchinda, Jonathan M Grimes, Wen-Yang Tsai, Chih-Yun Lai, Wei-Kung Wang, Prida Malasit, Jeremy Farrar, Cameron P Simmons, Z Hong Zhou, Felix A Rey, Juthathip Mongkolsapaya & Gavin R Screaton Nat. Immunol. 16, 170–177 (2015); published online 15 December 2014; corrected after print 27 February 2015
Collaboration
Dive into the Amonrat Jumnainsong's collaboration.
Thailand National Science and Technology Development Agency
View shared research outputs